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Skin-inﬁltrating T lymphocytes are thought to play a major role in the pathogenesis of cutaneous lupus erythematosus
(CLE). In this study, we investigated the role of the chemokine receptor 4 (CCR4) and its ligand thymus- and activation-
regulated chemokine (TARC/CCL17) for the recruitment of T cells in inﬂamed skin of patients with CLE. We found
significant numbers of CCR4þ T lymphocytes in the skin of all patients with CLE. Interestingly, a subset of patients
with disseminated scarring skin involvement were characterized by both lesional and circulating CD8þ T cells ex-
pressing CCR4. Destruction of epidermal and adnexal structures was histomorphologically associated with CCR4þ
cytotoxic T cells invading basal layers of the epidermis where keratinocytes showed apoptotic death. The CCR4 ligand
TARC/CCL17 was strongly expressed in skin lesions and elevated in the serum of CLE patients. The functional
relevance of lymphocytic CCR4 expression could be conﬁrmed by TARC/CCL17-specific in vitromigration assays. Our
investigations suggest that CCR4 and TARC/CCL17 play a role in the pathophysiology of CLE. In particular, cytotoxic
CD8þ T cells expressing CCR4 appear to be involved in scarring subtypes of CLE.
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Lupus erythematosus (LE) is an autoimmune disorder with a
broad clinical spectrum reaching from primarily cutaneous
manifestations (CLE) up to systemic disease (SLE). Frequent
cutaneous subtypes of LE are the scarring chronic discoid
LE (CDLE) and the non-scarring subacute CLE (SCLE). Pa-
tients suffering from CDLE are characterized by scarring
discoid plaques, ranging from localized to disseminated
variants. SCLE patients are characterized by nummular or
gyrated erythematosquamous lesions, predominantly in
sun-exposed areas without scarring. Histological analyses
of CLE lesions typically reveal dense CD3þ junctional and
periadnexal infiltrates (Tebbe et al, 1995). These supposedly
autoaggressive T lymphocytes are thought to play a signif-
icant role in the pathogenesis of CLE lesions.
A little more than 10 y ago, studies addressing the
immunobiology of T cell trafficking provided the first insights
into the molecular regulation of T cell homing to the skin
(Robert and Kupper, 1999). It could be shown that naı¨ve T
cells express adhesion molecules like L-selectin on their
surface, which allow them to enter lymph nodes via high
endothelial venules expressing appropriate ligands such as
peripheral node adressin. Once T cells become activated by
skin-derived antigen-presenting dendritic cells in draining
lymph nodes, they proliferate, express activation and ef-
fector molecules, and undergo the transition to memory T
cells (Sallusto et al, 2000). During this transition, some ef-
fector and memory T cells acquire new molecular keys such
as the cutaneous lymphocyte antigen (CLA), which allow
them to preferentially enter inflamed skin where the appro-
priate ligands are expressed on cutaneous microvascular
endothelial cells (Tietz et al, 1998). It could be shown that
the majority of T cells in inflamed skin lesions such as atopic
dermatitis, psoriasis vulgaris, lichen planus, discoid lupus
erythematosus, and cutaneous T cell lymphoma indeed ex-
press CLA on their cell surface (Heald et al, 1993; Nakamura
et al, 1998). The majority of CLAþ memory T cells express
the chemokine receptor (CCR)4 (Campbell et al, 1999). With
regard to T cell trafficking into inflamed skin, recent studies
have highlighted the role of CCR4 and its ligand thymus-
and activation-regulated chemokine (TARC/CCL17) (Schon
et al, 2003). Increased expression of CCR4 was demon-
strated in atopic dermatitis (Wakugawa et al, 2001), psoria-
sis (Inaoki et al, 2003), and in cutaneous T cell lymphoma
(Kallinich et al, 2003). Interaction between CCR4 and its
ligand TARC/CCL17 on activated endothelial cells mediates
T cell extravasation by stimulating integrin-dependent ad-
hesion of CLAþ T cells to intercellular adhesion molecule-1
(Campbell et al, 1999).
In this study, we investigated the expression of CCR4 on
T lymphocytes in both skin and peripheral blood of patients
suffering from CLE. We show that significant numbers of
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lesional T lymphocytes express CLA and CCR4. Important-
ly, the coexpression CLAþ and CCR4þ on lesional and
circulating CD8þ T lymphocytes defines a subset of CLE
patients characterized by disseminated scarring lesions.
Destruction of epidermal and adnexal structures was as-
sociated with infiltration of CD8þ T cells largely expressing
the cytotoxic molecule granzyme B. Increased TARC/
CCL17 levels were found in lesional skin and serum of
CLE patients. Importantly, CCR4-expressing lymphocytes
isolated from the blood of CDLE patients showed TARC/
CCL17-specific in vitro migration, confirming the functional
relevance of our findings.
Results
Enhanced expression of CCR4 on lesional CD8þ T
lymphocytes identiﬁes a subset of patients with scar-
ring CDLE CLE lesions are immunohistologically charac-
terized by a dense junctional and perivascular T cellular
infiltrate, primarily composed of CD4þ and CD8þ cells
(Fig 1a–c). In initial studies, we further investigated infiltrat-
ing lymphocytes by immunohistochemistry for the homing
molecules CLA and CCR4. As expected, large numbers of
CLA-expressing lymphocytes were present in skin lesions
of CDLE, SCLE, and SLE when compared with healthy
controls. Figure 1 shows a semiquantitative analysis with
numbers of cells per high-power field of view. Furthermore,
as detailed in Fig 1e, significantly increased expression of
CCR4 was also found in lesions of CDLE when compared
with healthy controls (po0.01).
We consistently noted a prominent infiltration with
CD8þ T cells in lesions from patients with scarring sub-
types of CLE. To assess the cytotoxic function of these
CD8þ T cells, we stained for the cytotoxic molecule gran-
zyme B. As shown in Fig 1f, patients with CDLE displayed
significantly increased expression of granzyme B (po0.01)
when compared with other LE subtypes and healthy con-
Figure 1
Immunohistological analyses of CD3, CD4, CD8, cutaneous lymphocyte antigen (CLA), CC receptor (CCR)4, and granzyme B expression.
Lesional skin biopsies were taken from patients with localized chronic discoid lupus erythematosus (lCDLE) (n¼5), disseminated CDLE (dCDLE)
(n¼ 4), subacute cutaneous LE (SCLE) (n¼ 11), systemic LE (SLE) (n¼ 5), and healthy controls (n¼5). Stainings were performed using the LSAB2 kit.
Sections were analyzed by two experienced dermatohistopathologists independently. Expression was evaluated as cells per high-power field
(  200 magnification). One point in the figure represents the mean results of the two investigators.
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trols. Significant differences between patients suffering from
localized and disseminated CDLE were not found. Thus,
strong expression of granzyme B was closely associated
with epidermal and adnexal destruction. Representative
clinical, histomorphological, and immunohistochemical
findings of a patient suffering from disseminated scaring
CDLE are depicted in Fig 2.
To confirm the expression of CCR4 on lesional CD8þ
T cells, immunofluorescence double staining was performed.
The analyses revealed expression of CCR4 on CD8þ infiltrat-
ing T lymphocytes in all of the four patients with disseminated
CDLE (dCDLE). A representative result is shown in Fig 2h.
dCDLE is associated with circulating CD8þT cells ex-
pressing CLA and CCR4 Subsequently, we investigated
the expression of skin homing molecules on circulating
lymphocytes by flow cytometry. Significantly increased
numbers of CD4þ T cells expressing CLA were present in
peripheral blood mononuclear cells of patients with dCDLE
and psoriasis when compared with healthy controls (Fig 3a).
Furthermore, the percentage of circulating CD4þT lymph-
ocytes expressing CCR4 was significantly higher in all in-
vestigated skin diseases when compared with healthy
controls (Fig 3b). As a consequence, elevated numbers of
CD4þ T lymphocytes expressing both CLA and CCR4
were found in patients with dCDLE and psoriasis (Fig 3c).
Most importantly, we detected significantly increased num-
bers of circulating CD8þ T cells expressing CLA and CCR4
exclusively in patients with disseminated discoid LE
(Fig 3d–f). This corresponds to the histopathological find-
ings described above in this subgroup of patients. Repre-
sentative flow cytometric results are depicted in Fig 4.
Figure 2
Representative clinical and immunohistochemical findings in a patient suffering from scarring discoid lupus erythematosus (LE). Clinical
investigation revealed scarring disseminated erythematosquamous plaques (a, b). Skin lesions were immunohistologically characterized by a dense
junctional and perivascular lymphocytic infiltrate primarily composed of T cells, with a slight majority of CD4þ T cells (c) over CD8þ T cells (d).
Furthermore, a high expression of cutaneous lymphocyte antigen (CLA) (e), CC receptor (CCR)4 (f), and granzyme B (g) was found (original mag-
nification:  200). Immunofluorescence double staining for CD8 (fluorescein isothiocyanate, green) and CCR4 (TRITC, red) revealed the presence of
CCR4-expressing CD8þ T cells (yellow, ! ) in the upper dermis (h; original magnification:  400).
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Increased levels of TARC/CCL17 in the skin and blood
of CLE As the expression of CCR4 on lesional and circu-
lating lymphocytes in LE patients was increased, we analy-
zed the expression of the CCR4 ligand TARC/CCL17 in the
skin by immunohistochemistry and in serum by ELISA. A
high epidermal and perivascular expression of TARC/CCL17
was found in CDLE as well as in SCLE skin lesions (Fig 5a
and b). Additionally, elevated TARC/CCL17 serum levels
were found in all investigated LE subsets when compared
with healthy controls (Fig 5c).
CCR4 expression on CD4þ and CD8þ T lymphocytes
in dCDLE patients is functionally relevant To confirm the
functional relevance of CCR4 on the surface of circulating T
lymphocytes, we performed TARC/CCL17-directed chemo-
kine migration assays in vitro. A TARC/CCL17 concentration
of 40 ng per mL was found to be optimal for strong migra-
tion of CD4þ and CD8þ cells of patients with dCDLE (Fig
6). Migrated cells were exclusively CCR4 positive. Using the
optimal TARC/CCL17 concentration, a mean chemotactic
index of 11.1 for CD4þ cells and 12.7 for CD8þ cells was
found. In healthy controls, the chemotactic index ranged
between 0.7 and 1.7. Differences were highly significant
(po0.01). The relative TARC-directed migration of CD4þ
CCR4þ lymphocytes (migrated cells/not migrated cells)
ranged from 73% to 95% (mean 87.5  5 SEM, control
without TARC: from 0% to 19%, mean 7.5  4.1 SEM); the
TARC directed migration of CD8þ CCR4þ lymphocytes
ranged from 88% to 94%, with a mean of 91.2%  2.1 SEM
(control without TARC: from 0% to 23%, mean 8.25%  5.1
SEM).
Discussion
In this study, we found strong expression of the skin homing
molecules CLA and CCR4þ on lesional and circulating T
lymphocytes in CLE. CLA is well known to be involved in
skin-directed inflammation (Rossiter et al, 1994). Recently, a
possible pathogenetic role for CCR4 in skin diseases has
been considered. Nakatani et al (2001) described an in-
creased expression of CCR4 on lesional and circulating
CD4þ lymphocytes in patients suffering from atopic der-
matitis. Wakugawa et al (2001) found elevated expression
Figure 2
Continued
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of CCR4 on peripheral blood CD4þ lymphocytes in atopic
dermatitis, which correlated with disease activity. Inaoki
et al (2003) published data of a slightly, but significantly
elevated expression of CCR4 on peripheral blood CD8þ
cells in psoriasis as compared with healthy volunteers. Fe-
renczi et al (2002) and Kallinich et al (2003) found circulating
and lesional T lymphocytes in cutaneous T cell lymphoma
mainly to be CCR4þ . CCR4 expression in CLE has not been
analyzed so far. Hase et al (2001), however, found an in-
creased CCR4 expression on CD4þ T lymphocytes in active
SLE. Furthermore, in lupus nephritis, CCR4þ CD4þ T
lymphocytes accumulate in renal tissues (Yamada et al, 2002).
Skin lesions from patients with localized and dissemi-
nated CDLE were characterized by a high number of infil-
trating CD8þ CCR4þ T lymphocytes. Histomorphologi-
cally, lesional CD8þ T cells expressing the cytotoxic
molecule granzyme B were associated with destruction of
epidermal and adnexal structures in this subgroup of pa-
tients. Interestingly, in the blood we found CD8þ T cells
expressing both CLA and CCR4 exclusively in patients with
disseminated scarring CDLE. This novel finding has not
been described to date. We believe that the increased
numbers of circulating CCR4þ CD8þ T cells found in pa-
tients with disseminated CDLE reflect the expansion of
cytotoxic T lymphocytes that recognize epidermal antigens
and therefore are able to destroy keratinocytes.
To confirm the pathogenetic relevance of lymphocytic
CCR4 expression in CLE, we subsequently analyzed the
presence of the CCR4 ligand TARC/CCL17 in the skin and
serum of LE patients. TARC/CCL17 had previously been
Figure 3
Flow cytometric analyses of cutaneous lymphocyte antigen (CLA) and CC receptor (CCR)4 expression. Flow cytometric analyses of CLA and
CCR4 were performed on lymphocytes isolated from peripheral blood of lupus erythematosus (LE) patients (localized chronic discoid LE (lCDLE)
(n¼ 5); disseminated CDLE (dCDLE) (n¼4); subacute cutaneous LE (SCLE) (n¼ 11); systemic LE (SLE) (n¼ 5)); and controls (healthy volunteers
(n¼ 5); psoriasis (n¼5); zoster (n¼5)). The mean percent of CD4þ or CD8þ T lymphocytes expressing the indicated molecules  SEM are shown
(po0.05; po0.01; ns¼ not significant when compared with healthy controls).
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shown to be elevated in several other skin disorders. For
example, in atopic dermatitis increased serum TARC/
CCL17 levels were associated with disease severity (Kaki-
numa et al, 2003a, b; Hijnen et al, 2004). Serum TARC/
CCL17 levels also reflected the disease activity in mycosis
fungoides (Kakinuma et al, 2003a, b). Furthermore, in SLE
the plasma level of TARC/CCL17 was elevated in active
disease and correlated with disease severity (Kallinich et al,
2003). Additionally, we revealed strong migration of CCR4-
expressing T lymphocytes from CDLE patients toward the
CCR4 ligand TARC/CCL17 in chemokine migration assays,
ascertaining the functional relevance of lymphocytic CCR4
expression. We hypothesize that the production of TARC/
CCL17 and the expression of CCR4 on T lymphocytes
might represent an important biological amplification mech-
anism to promote inflammatory responses in skin lesions of
CLE. This has been described in other inflammatory skin
diseases such as psoriasis and atopic dermatitis.
At present, little is known about the critical factors in the
generation of skin-homing T lymphocytes in CLE as well as
in other cutaneous immune responses mediated by T
lymphocytes. In an experimental mouse model for contact
hypersensitivity, Dudda et al (2004) recently reported that
intracutaneous but not intravenous injections of haptenized
bone marrow-derived dendritic cells were able to induce
skin-homing CD8þ T cells that express E-selectin-binding
molecules (the murine equivalent of CLA) as well as CCR4
and were responsible for effector functions in cutaneous
contact allergy. The authors assumed a crucial role for the
tissue microenvironment and the quality of the antigen-
presenting dendritic cells in the instruction of T cells for tis-
sue-selective homing. Based on these observations, we
envision the following pathophysiologic scenario for CLE:
skin-derived dendritic cells loaded with apoptotic keratin-
ocytes induced by UV irradiation stimulate antigen-specific T
lymphocytes expressing homing molecules such as CLA and
CCR4 that confer the capacity to enter inflamed skin. Local
expression of adhesion molecules and chemokines such as
E-selectin and TARC/CCR17 subsequently help to attract
these activated T lymphocytes into lesional skin of CLE.
Figure 4
Representative findings of cutaneous lymphocyte antigen (CLA)
and CC receptor (CCR)4 expression on CD8þ T cells. Typical flow
cytometric findings of peripheral blood lymphocytes of a patient suf-
fering from disseminated chronic discoid lupus erythematosus (dCDLE)
and a healthy volunteer are depicted. Numbers represent the percent-
age of CD8þ T cells coexpressing CLAþ or CCR4þ .
Figure5
Thymus- and activation regulated chemokine (TARC/CCL17) ex-
pression in the skin and serum. The expression of TARC/CCL17 in
skin and serum was analyzed by immunohistochemistry and ELISA,
respectively. In cutaneous lupus erythematous (CLE) lesions, strong
TARC/CCL17 expression (red) was detectable in the epidermis and in
perivascular areas in all investigated subsets (a). (b) Representative
immunohistological findings in a patient with disseminated chronic
discoid lupus erythematosus (dCDLE). Serum analyses by ELISA re-
vealed significantly elevated TARC/CCL17 serum levels in all investi-
gated LE subsets when compared with healthy controls (c). Mean
levels  SEM are depicted.
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Taken together, our findings suggest that CLA and CCR4
expression on lesional and circulating T lymphocytes plays
a role in the pathogenesis of CLE. Importantly, our results
suggest that CLAþ and CCR4þ cytotoxic T cells partic-
ipate in specific destruction of epidermal and adnexal
structures in scarring CDLE.
Patients and Methods
Patients and healthy donors Twenty-five LE patients (17 female,
eight male) who had an acute exacerbation of their LE with recent
inflammatory skin lesions were included in the study. Five patients
suffered from scarring localized CDLE (lCDLE), four from scarring
dCDLE, 11 from SCLE, and five from SLE, with acute skin lesions
(macular erythema or malar rash). Detailed clinical information of
the investigated patients is provided in a supplementary table
published on the web site (Table S1). Additionally, samples from
five healthy donors, five patients with exacerbated psoriasis, and
five patients with herpes zoster were analyzed for control purpos-
es. A diagnosis of LE was established based on standard criteria
including clinical symptoms, histological and immunohistochemi-
cal findings as well as on detection of antinuclear antibodies. Lo-
calized and disseminated CDLE were differentiated by the extent
of skin involvement. lCDLE is restricted to one body region only;
dCDLE involves more that one region (e.g., head and shoulders).
dCDLE was separated from SCLE by the development of scarring
skin lesions. All skin samples included were taken for diagnostic
purposes immediately when the patients presented at our depart-
ment with acute skin lesions prior to any treatment. Blood samples
were taken at the same time. Skin lesions selected for biopsy had
developed recently according to the patients’ history. The age of
patients and donors ranged between 18 and 72 y, respectively. All
of them were Caucasian. Informed consent for participating in this
study was obtained from all donors. The study was performed
according to local ethical guidelines as well as the Declaration of
Helsinki and was approved by the local regulatory committee.
Immunohistological staining Serial sections were prepared from
formalin-fixed, paraffin-embedded skin biopsies. Monoclonal an-
tibodies (mAb) specific for CCR4 (1G1, biotin), CLA (HECA452)
(both from BD-Pharmingen, San Diego, California), TARC/CCL17
(ETR01, from R&D Systems, Minneapolis, Minnesota), CD4 (1F6,
Novocastra, Newcastle, UK), CD3 (F7238), CD8 (C8/144B), CD20
(L26), and granzyme B (GrB7) (all from DAKO, Hamburg, Germany)
were used for primary staining. Appropriate isotype-matched con-
trols were included. The specimens were incubated with the first
antibody for 2 h. Secondary staining was performed using the
LSAB2 staining kit (DAKO). Tetramethylrhodamineisothiocyanate
(TRITC)-conjugated anti-mouse and fluorescein isothiocyanate
(FITC)-labeled rabbit-streptavidin were used for fluorescence dou-
ble staining (both from DAKO). Results were evaluated on blinded
specimens by two experienced dermatopathologists independently.
Cells were counted per high-power field (  200), TARC/CCL17
expression was detected semiquantitatively (0,þ ,þ þ ,þ þ þ ).
Flow cytometric analysis PBMC were isolated from heparinized
venous blood using density gradient centrifugation over Lympho-
prep (Axis-Shield PoC AS, Norway). The following mAb were used
in flow cytometric analyses: CCR4 phycoerythrin (PE) and biotin
(1G1), CLA FITC (HECA452), CD3 PE/PerCP (SK7), CD4 PerCP
(SK3), CD8 FITC (SK1), CD8 PerCP (SK3), all from BD Pharmingen
(Franklin Lakes, New Jersey). Isotype matched controls were in-
cluded. Analyses were performed on freshly isolated and on frozen
material, stored at 801C in RPMI medium containing 10% fetal
calf serum and 10% dimethyl sulfoxide. Results of frozen and
freshly isolated material were controlled carefully; significant dif-
ferences were not found. Three-color flow cytometry was per-
formed by incubation of 5  105 PBMC with the indicated mAb.
After staining, cells were fixed with Cytofix Buffer (BD Pharmingen)
and analyzed using a FACScan flow cytometer and CellQuest
software (BD Pharmingen). Further evaluations were performed
with WinMDI 2.8.
Serum TARC/CCL17-Level Serum levels of TARC/CCL17 were
determined by ELISA (Quantikine, R&D Systems), following the
manufacturers’ operation protocol.
Chemokine migration assay Chemotaxis assays were performed
with PBMC in 24-well plates with transwell inserts of 5 mm pore
size (all material from Costar, Cambridge, Masachussetts). 5  105
cells were plated on the cover membrane in RPMI-1640 medium
containing 0.4% fetal bovine serum and incubated at 371C. Serial
dilutions of recombinant TARC/CCL17 (R&D Systems) were placed
in the bottom chamber to determine the optimal concentration for
migration. For determination of the chemotatic index, 20 mL of the
cells that had migrated to the lower well after 2 h at 371C and 20 mL
of the sample in the upper well were collected in TruCOUNT tubes
(BD Pharmingen) and analyzed by flow cytometry. These Tru-
COUNT tubes include a lyophilized pellet with a defined number of
fluorescent beads. The absolute number of investigated cells in
Figure 6
Thymus- and activation regulated
chemokine (TARC/CCL17)-directed
migration of CD4þ and CD8þ T lym-
phocytes. The functional relevance of
chemokine receptor (CCR)4 expression
found on T lymphocytes isolated from
peripheral blood of disseminated chronic
discoid lupus erythematosus (dCDLE)
patients was investigated by an in vitro
chemotactic migration assay. Migration
was evaluated by determining the chemo-
tactic index (specifically migrated cells di-
vided by unspecifically migrated cells).
Results revealed significant migration of
peripheral CD4þ CCR4þ and CD8þ
CCR4þ lymphocytes from dCDLE
patients at an optimal TARC/CCL17
concentration of 40 ng per mL when
compared with healthy controls (po
0.01). mean levels of the chemotactic in-
dex  SEM are depicted.
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both samples was determined by comparing the relative count of
investigated CD4þ CCR4þ and CD8þ CCR4þ cells by the rel-
ative count of fluorescence beads, using the following equation:
(number of events in region containing cells/number of events in
absolute count bead region)  (absolute number of beads per test/
test volume)¼ absolute count of cells per volume.
Basal migration and TARC/CCL17-directed migration were
evaluated by determining the chemotactic index (specifically mi-
grated cells divided by unspecifically migrated cells). Experiments
were performed in triplicate and repeated at least three times.
Statistical analysis The expression of CCR4, CD4, CD8, and
Granzyme B in flow cytometry and immunohistochemistry was
evaluated by nonparametric tests. The Kruskal–Wallis test was
used to analyze differences among the groups, followed by the
unpaired Mann–Whitney test for comparisons between any two
of the groups. An identical statistical process was performed to
compare TARC/CCL17 serum levels. Probabilities o0.05 were
considered to be significant (), p-valueso0.01 as highly significant
(). Results are given in mean  SEM.
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